Oldest pages

Showing below up to 50 results in range #501 to #550.

501. Qin, Y (10:37, 18 November 2024)
502. Liu, W (10:37, 18 November 2024)
503. Zhou, X (10:38, 18 November 2024)
504. Li, Y (10:38, 18 November 2024)
505. Wang, L (10:38, 18 November 2024)
506. Attia, S (10:44, 20 November 2024)
507. Eickhoff, J (10:45, 20 November 2024)
508. Wilding, G (10:45, 20 November 2024)
509. McNeel, D (10:46, 20 November 2024)
510. Blank, J (10:47, 20 November 2024)
511. Ahuja, H (10:47, 20 November 2024)
512. Jumonville, A (10:47, 20 November 2024)
513. Eastman, M (10:48, 20 November 2024)
514. Shevrin, D (10:48, 20 November 2024)
515. Glode, M (10:48, 20 November 2024)
516. Alberti, D (10:48, 20 November 2024)
517. Staab, M (10:49, 20 November 2024)
518. Publication: Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer (10:52, 20 November 2024)
519. Staab, MJ (10:54, 20 November 2024)
520. Horvath, D (10:54, 20 November 2024)
521. Straus, J (10:54, 20 November 2024)
522. Marnocha, R (10:55, 20 November 2024)
523. Liu, G (10:55, 20 November 2024)
524. Publication: A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy (11:05, 20 November 2024)
525. Publication: Randomized, Double-Blind, Placebo-Controlled Trial of Polyphenon E in Prostate Cancer Patients before Prostatectomy: Evaluation of Potential Chemopreventive Activities (11:08, 20 November 2024)
526. Beer, T (11:09, 20 November 2024)
527. Ryan, CW (11:09, 20 November 2024)
528. Venner, PM (11:10, 20 November 2024)
529. Petrylak, DP (11:20, 20 November 2024)
530. Chatta, GS (11:20, 20 November 2024)
531. Redfern, CH (11:21, 20 November 2024)
532. Ruether, DJ (11:26, 20 November 2024)
533. Fehrenbacher, L (11:28, 20 November 2024)
534. Publication: Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L Carnitine (11:29, 20 November 2024)
535. Saleh, MN (11:30, 20 November 2024)
536. Waterhouse, DM (11:30, 20 November 2024)
537. Carducci, MA (11:38, 20 November 2024)
538. Vicario, D (11:38, 20 November 2024)
539. Dreicer, R (11:38, 20 November 2024)
540. Higano, CS (11:39, 20 November 2024)
541. Chi, KN (11:39, 20 November 2024)
542. Publication: Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer (11:43, 20 November 2024)
543. Henner, WD (11:44, 20 November 2024)
544. Arroyo, A (11:44, 20 November 2024)
545. Clow, FW (11:44, 20 November 2024)
546. Jacot, W (11:49, 20 November 2024)
547. Firmin, N (11:49, 20 November 2024)
548. Roca, L (11:50, 20 November 2024)
549. Topart, D (11:50, 20 November 2024)
550. Gallet, S (11:50, 20 November 2024)